Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effects of Acute and Chronic Empagliflozin Heart Failure
Sponsor: Yale University
Summary
This is a 60-patient randomized, double-blind, placebo-controlled mechanistic study to understand the utility of empagliflozin in worsening heart failure (HF) patients with or without diabetes. Participants will be randomized to empagliflozin or placebo for 6 weeks, followed by a crossover of placebo patients to active therapy at 6 weeks-12 weeks.
Official title: Renal Mechanistic Effects of Acute and Chronic Empagliflozin in Heart Failure
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-08-04
Completion Date
2025-11
Last Updated
2024-12-18
Healthy Volunteers
No
Conditions
Interventions
Empagliflozin 10 mg
Empagliflozin 10mg
Placebo
Empagliflozin matched placebo tablet
Locations (2)
Yale New Haven Hospital
New Haven, Connecticut, United States
Yale University
New Haven, Connecticut, United States